9 active not recruiting, 6 recruiting, 3 completed. 18 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Active not recruiting 9, Recruiting 6, Completed 3 |
| Phase 2 | 2 | Active not recruiting 2 |
Follow Mb02: new trials by email Literature Review of Mb02 trials Research Report on Mb02
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2026-10-01 | 2026-09-25 |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial Atezolizumab, Bevacizumab, Biospecimen Collection - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 226 | 2026-02-26 | 2026-08-17 |
| Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer Bevacizumab, Biospecimen Collection, Carboplatin - Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 255 | 2026-01-27 | 2026-10-23 |
| Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 3 | Recruiting | NRG Oncology | 880 | 2025-03-12 | 2026-08-07 |
| Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial Bevacizumab, Capecitabine, Cetuximab - Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 408 | 2024-04-10 | 2026-09-24 |
| Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers Atezolizumab, Bevacizumab, Biospecimen Collection - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 430 | 2023-03-13 | 2026-10-01 |
| Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 300 | 2020-12-28 | 2026-10-27 |
| Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study Atezolizumab, Bevacizumab, Biospecimen Collection - Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 120 | 2018-01-19 | 2026-10-26 |
| Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Atezolizumab, Bevacizumab, Computed Tomography - Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 444 | 2017-06-23 | 2026-10-26 |
| Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Bevacizumab, Capecitabine, Carboplatin - Borderline Ovarian Mucinous Tumor, Ovarian Mucinous Cystadenocarcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 50 | 2010-10-12 | 2026-08-28 |
| Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Computed Tomography - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 692 | 2010-09-27 | 2026-05-29 |
| Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer Bevacizumab, Laboratory Biomarker Analysis, Letrozole - Invasive Breast Carcinoma, Recurrent Breast Carcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 394 | 2008-09-24 | 2026-08-28 |
| Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Bevacizumab, Carboplatin, Cisplatin - Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 403 | 2008-08-08 | 2026-10-22 |
| Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Docetaxel - Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1052 | 2007-12-06 | 2025-12-30 |
| Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Bevacizumab, Laboratory Biomarker Analysis, Octreotide Acetate - Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 427 | 2007-12-01 | 2026-10-22 |
| Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer Bevacizumab, Cyclophosphamide, Doxorubicin Hydrochloride - Breast Adenocarcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 4994 | 2007-11-02 | 2026-10-01 |
| Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Bevacizumab, Cisplatin, Docetaxel - Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Phase 3 | Completed | National Cancer Institute (NCI) | 1501 | 2007-07-19 | 2026-06-23 |
| Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Bevacizumab, Fluorouracil, Leucovorin - Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7 | Phase 3 | Completed | National Cancer Institute (NCI) | 2431 | 2005-09-06 | 2026-08-25 |
Fallopian Tube Neoplasms (4) · Ovarian Neoplasms (4) · Colorectal Neoplasms (3) · Brenner Tumor (2) · Carcinoma (2) · Lymphoid Interstitial Pneumonia (2) · Squamous Cell Carcinoma of Head and Neck (2) · Adenocarcinoma, Clear Cell (1) · Adenocarcinoma, Mucinous (1) · Appendiceal Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Neoplasms (1) · Endometrial Neoplasms (1)
National Cancer Institute (NCI) (14) · NRG Oncology (2) · City of Hope Medical Center (1) · ECOG-ACRIN Cancer Research Group (1)
United States (18) · Puerto Rico (5) · Canada (4) · South Africa (4) · Peru (3) · Japan (2) · South Korea (2) · Ireland (1)
Aarti Bhatia (1) · Al B Benson (1) · Amanda N Fader (1) · David M Gershenson (1) · Heather A Wakelee (1) · Helena A Yu (1) · Hope S Rugo (1) · James C Yao (1) · Jennifer Y Wo (1) · John K Chan (1) · Kathy D Miller (1) · Michael Lidsky (1) · Mustafa Raoof (1)
PMID 37185961, PMID 26933849, PMID 27138575, PMID 28384065, PMID 28438473, PMID 28646344, PMID 29129443, PMID 29789969, PMID 30040523, PMID 30054636, PMID 31276981, PMID 31618129, PMID 31722153, PMID 34616010, PMID 34726788, PMID 35226083, PMID 41666849, PMID 42525921
U10CA180868 (8), U10CA180820 (7), U10CA021115 (4), U10CA027469 (3), P30CA033572 (1), U10CA031946 (1), U10CA032102 (1), U10CA180821 (1), U10CA180888 (1)